A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine
Current efforts to reduce the global burden of malaria are threatened by the rapid spread throughout Asia of Plasmodium falciparum resistance to artemisinin-based combination therapies, which includes increasing rates of clinical failure with dihydroartemisinin plus piperaquine (PPQ) in Cambodia. Us...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2017-05-01
|
Series: | mBio |
Online Access: | http://mbio.asm.org/cgi/content/full/8/3/e00303-17 |
id |
doaj-141528680c524d41a85c83672164db34 |
---|---|
record_format |
Article |
spelling |
doaj-141528680c524d41a85c83672164db342021-07-02T01:26:35ZengAmerican Society for MicrobiologymBio2150-75112017-05-0183e00303-1710.1128/mBio.00303-17A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug PiperaquineSatish K. DhingraDevasha RedhiJill M. CombrinckTomas YeoJohn OkomboPhilipp P. HenrichAnnie N. CowellPurva GuptaMatthew L. StegmanJonathan M. HokeRoland A. CooperElizabeth WinzelerSachel MokTimothy J. EganDavid A. FidockThomas E. WellemsCurrent efforts to reduce the global burden of malaria are threatened by the rapid spread throughout Asia of Plasmodium falciparum resistance to artemisinin-based combination therapies, which includes increasing rates of clinical failure with dihydroartemisinin plus piperaquine (PPQ) in Cambodia. Using zinc finger nuclease-based gene editing, we report that addition of the C101F mutation to the chloroquine (CQ) resistance-conferring PfCRT Dd2 isoform common to Asia can confer PPQ resistance to cultured parasites. Resistance was demonstrated as significantly higher PPQ concentrations causing 90% inhibition of parasite growth (IC90) or 50% parasite killing (50% lethal dose [LD50]). This mutation also reversed Dd2-mediated CQ resistance, sensitized parasites to amodiaquine, quinine, and artemisinin, and conferred amantadine and blasticidin resistance. Using heme fractionation assays, we demonstrate that PPQ causes a buildup of reactive free heme and inhibits the formation of chemically inert hemozoin crystals. Our data evoke inhibition of heme detoxification in the parasite’s acidic digestive vacuole as the primary mode of both the bis-aminoquinoline PPQ and the related 4-aminoquinoline CQ. Both drugs also inhibit hemoglobin proteolysis at elevated concentrations, suggesting an additional mode of action. Isogenic lines differing in their pfmdr1 copy number showed equivalent PPQ susceptibilities. We propose that mutations in PfCRT could contribute to a multifactorial basis of PPQ resistance in field isolates.http://mbio.asm.org/cgi/content/full/8/3/e00303-17 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Satish K. Dhingra Devasha Redhi Jill M. Combrinck Tomas Yeo John Okombo Philipp P. Henrich Annie N. Cowell Purva Gupta Matthew L. Stegman Jonathan M. Hoke Roland A. Cooper Elizabeth Winzeler Sachel Mok Timothy J. Egan David A. Fidock Thomas E. Wellems |
spellingShingle |
Satish K. Dhingra Devasha Redhi Jill M. Combrinck Tomas Yeo John Okombo Philipp P. Henrich Annie N. Cowell Purva Gupta Matthew L. Stegman Jonathan M. Hoke Roland A. Cooper Elizabeth Winzeler Sachel Mok Timothy J. Egan David A. Fidock Thomas E. Wellems A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine mBio |
author_facet |
Satish K. Dhingra Devasha Redhi Jill M. Combrinck Tomas Yeo John Okombo Philipp P. Henrich Annie N. Cowell Purva Gupta Matthew L. Stegman Jonathan M. Hoke Roland A. Cooper Elizabeth Winzeler Sachel Mok Timothy J. Egan David A. Fidock Thomas E. Wellems |
author_sort |
Satish K. Dhingra |
title |
A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine |
title_short |
A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine |
title_full |
A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine |
title_fullStr |
A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine |
title_full_unstemmed |
A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine |
title_sort |
variant pfcrt isoform can contribute to plasmodium falciparum resistance to the first-line partner drug piperaquine |
publisher |
American Society for Microbiology |
series |
mBio |
issn |
2150-7511 |
publishDate |
2017-05-01 |
description |
Current efforts to reduce the global burden of malaria are threatened by the rapid spread throughout Asia of Plasmodium falciparum resistance to artemisinin-based combination therapies, which includes increasing rates of clinical failure with dihydroartemisinin plus piperaquine (PPQ) in Cambodia. Using zinc finger nuclease-based gene editing, we report that addition of the C101F mutation to the chloroquine (CQ) resistance-conferring PfCRT Dd2 isoform common to Asia can confer PPQ resistance to cultured parasites. Resistance was demonstrated as significantly higher PPQ concentrations causing 90% inhibition of parasite growth (IC90) or 50% parasite killing (50% lethal dose [LD50]). This mutation also reversed Dd2-mediated CQ resistance, sensitized parasites to amodiaquine, quinine, and artemisinin, and conferred amantadine and blasticidin resistance. Using heme fractionation assays, we demonstrate that PPQ causes a buildup of reactive free heme and inhibits the formation of chemically inert hemozoin crystals. Our data evoke inhibition of heme detoxification in the parasite’s acidic digestive vacuole as the primary mode of both the bis-aminoquinoline PPQ and the related 4-aminoquinoline CQ. Both drugs also inhibit hemoglobin proteolysis at elevated concentrations, suggesting an additional mode of action. Isogenic lines differing in their pfmdr1 copy number showed equivalent PPQ susceptibilities. We propose that mutations in PfCRT could contribute to a multifactorial basis of PPQ resistance in field isolates. |
url |
http://mbio.asm.org/cgi/content/full/8/3/e00303-17 |
work_keys_str_mv |
AT satishkdhingra avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT devasharedhi avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT jillmcombrinck avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT tomasyeo avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT johnokombo avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT philippphenrich avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT anniencowell avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT purvagupta avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT matthewlstegman avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT jonathanmhoke avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT rolandacooper avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT elizabethwinzeler avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT sachelmok avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT timothyjegan avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT davidafidock avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT thomasewellems avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT satishkdhingra variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT devasharedhi variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT jillmcombrinck variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT tomasyeo variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT johnokombo variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT philippphenrich variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT anniencowell variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT purvagupta variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT matthewlstegman variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT jonathanmhoke variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT rolandacooper variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT elizabethwinzeler variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT sachelmok variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT timothyjegan variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT davidafidock variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine AT thomasewellems variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine |
_version_ |
1721344941039288320 |